News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
525,626 Results
Type
Article (39352)
Company Profile (187)
Press Release (486087)
Section
Business (157359)
Career Advice (1773)
Deals (30061)
Drug Delivery (105)
Drug Development (73964)
Employer Resources (137)
FDA (12121)
Job Trends (11955)
News (281031)
Policy (30383)
Tag
Academia (2052)
Alliances (47503)
Alzheimer's disease (1113)
Approvals (12050)
Artificial intelligence (123)
Bankruptcy (280)
Best Places to Work (9141)
Biotechnology (96)
Breast cancer (95)
Cancer (933)
Cardiovascular disease (84)
Career advice (1466)
Cell therapy (192)
Clinical research (58892)
Collaboration (358)
Compensation (170)
COVID-19 (2532)
C-suite (82)
Data (947)
Diabetes (137)
Diagnostics (4134)
Drug pricing (97)
Earnings (56568)
Employer resources (124)
Events (71574)
Executive appointments (247)
FDA (12561)
Funding (274)
Gene therapy (165)
GLP-1 (650)
Government (4328)
Healthcare (13381)
Infectious disease (2620)
Inflammatory bowel disease (94)
Interviews (298)
IPO (12772)
Job creations (3152)
Job search strategy (1284)
Layoffs (376)
Legal (7963)
Lung cancer (154)
Manufacturing (177)
Medical device (6794)
Medtech (6798)
Mergers & acquisitions (17359)
Metabolic disorders (426)
Neuroscience (1369)
NextGen Class of 2024 (4671)
Non-profit (3129)
Northern California (1134)
Obesity (255)
Opinion (223)
Patents (94)
People (43043)
Pharmaceutical (80)
Phase I (18152)
Phase II (25636)
Phase III (19915)
Pipeline (414)
Policy (84)
Postmarket research (2309)
Preclinical (7392)
Radiopharmaceuticals (239)
Rare diseases (192)
Real estate (4446)
Regulatory (19338)
Research institute (1886)
Resumes & cover letters (278)
Southern California (971)
Startups (2864)
United States (9947)
Vaccines (604)
Weight loss (214)
Date
Today (100)
Last 7 days (658)
Last 30 days (3009)
Last 365 days (28541)
2024 (26119)
2023 (31723)
2022 (41341)
2021 (44313)
2020 (42455)
2019 (35582)
2018 (27180)
2017 (26639)
2016 (25492)
2015 (29296)
2014 (23178)
2013 (19380)
2012 (20672)
2011 (21311)
2010 (19632)
Location
Africa (736)
Arizona (101)
Asia (35181)
Australia (5532)
California (2479)
Canada (1044)
China (213)
Colorado (114)
Connecticut (107)
Europe (77834)
Florida (349)
Illinois (248)
Indiana (161)
Maryland (487)
Massachusetts (1937)
Michigan (85)
Minnesota (138)
New Jersey (797)
New York (764)
North Carolina (533)
Northern California (1134)
Ohio (104)
Pennsylvania (604)
South America (1047)
Southern California (971)
Texas (317)
Washington State (248)
525,626 Results for "novartis pharma ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug pricing
NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act.
October 21, 2024
·
2 min read
·
Tristan Manalac
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Mergers & acquisitions
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.
November 21, 2024
·
2 min read
·
Tristan Manalac
Deals
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.
June 20, 2024
·
10 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG.
April 30, 2024
·
3 min read
Mergers & Acquisitions
Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science
Novartis has disclosed roughly $19.4 billion in deals in the past five years. CEO Vas Narasimhan says there’s more to come.
November 21, 2024
·
2 min read
·
Annalee Armstrong
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
1 of 52,563
Next
